Increased resting heart rate is associated with worse outcomes in studies of mostly white populations, but its significance is not well established in African Americans persons whose cardiac comorbidities and structural abnormalities differ.
All participants provided written informed consent, and study protocols were approved by local institutional review boards. There was no financial compensation. The present study was approved with waiver of informed consent by the institutional review board of the Duke University Health System. Available data include demographic characteristics; comorbid conditions; medications; laboratory values; supine, 12-lead, digital electrocardiograms (ECGs) at examinations 1 and 3; and echocardiogram at examination 1. 13 The ECGs were recorded after an overnight fast and transmitted using a digital ECG recorder (MAC/PC; Marquette Electronics) to the electrocardiographic reading center at the University of Minnesota. The ECGs were then read using a computer algorithm prepared with the Minnesota Code Modular ECG Analysis System developed for clinical trials and population studies and validated previously. 13 Resting heart rates were obtained from the ECGs and underwent review by a physician if the reported heart rate was 40 beats per minute (bpm) or less or 150 bpm or higher or was accompanied by abnormal rhythm.
Study Population
For analysis of the primary end point of mortality, we created a cohort of all patients with examination 1 documentation of heart rate on ECG (cohort A). Patients with atrial or ventricular pacing at examination 1 as indicated by ECG atrioventricular or atrial fibrillation (Minnesota Code 6-8) were excluded from the analysis. 13 Secondary end point analyses were conducted in 2 subgroups of cohort A. For the analysis of heart failure hospitalization, we included participants surviving to 2005, when heart failure hospitalization surveillance began (cohort B). For the analysis of factors associated with elevated heart rate, we included participants who completed examination 3 and had documentation of heart rate on ECG at this follow-up (cohort C).
Outcomes
The primary outcome was all-cause mortality within 9 years after examination 1. Procedures to identify deaths in the Jackson Heart Study have been described previously. 14 In summary, data were generated from the following sources: annual follow-up, including interviews with participants and next of kin; the National Death Index from the Centers for Disease Control and Prevention (http://www.cdc.gov/nchs/ndi/index .htm); and physician and coroner reports reviewed by a medical record abstraction unit. All diagnoses were adjudicated by trained medical staff. We also assessed the cumulative incidence of heart failure hospitalization between 2005 and 2011 among participants who survived to January 1, 2005 (when surveillance for heart failure hospitalizations began), for participants in cohort B. Heart failure hospitalizations were adjudicated by trained and certified heart failure abstractors through December 31, 2011, at the time of the analysis and required (1) a discharge diagnosis of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 428 and/or underlying cause of death code I50 and (2) radiographic, hemodynamic, or ECG findings of heart failure or (3) autopsy finding of pulmonary edema or heart failure.
14 Any heart failure hospitalization occurring in a noncatchment area hospital was validated with additional data after participant consent. Trained medical staff also reviewed and adjudicated primary diagnoses by their corresponding ICD-9-CM codes. Fi-
Key Points
Question What is the prognostic utility of resting heart rate in African American individuals?
Findings In this cohort study of 5261 African American participants in the Jackson Heart Study, resting heart rate was associated with significantly increased mortality and heart failure hospitalization before and after adjustment for comorbid conditions. With adjustment, every 5-beats per minute increase in heart rate was associated with a significant 14% increase in the hazard of mortality and a significant 10% increase in the risk for heart failure hospitalization.
Meaning
Higher baseline heart rate is associated with increases in mortality and heart failure hospitalization among African American individuals in the Jackson Heart Study.
Covariates
Baseline variables obtained from examination 1 were demographic characteristics, comorbid conditions, self-reported physical activity and caffeine consumption, physical examination findings, laboratory test values, echocardiographic and ECG results, and medications. Among comorbid conditions, diagnoses of hypertension (blood pressure ≥140/90 mm Hg or use of blood pressure-lowering medications) and diabetes (fasting glucose level ≥126 mg/dL [to convert to millimoles per liter, multiply by 0.0555], hemoglobin A 1c level ≥6.5% [to convert to proportion of total hemoglobin, multiply by 0.01], or receiving diabetes medications) were based on physician examination findings or laboratory test values; diagnosis of atrial fibrillation was based on ECG evidence; and myocardial infarction, stroke, chronic lung disease, and smoking were selfreported. To determine the presence of heart failure at baseline, we applied modified Gothenburg criteria as developed and validated in the ARIC study. 15 To ascertain left ventricular hypertrophy, we used quantitative left ventricular mass measurement from 2-dimensional or M-mode echocardiography (older technique without 2-dimensional image) when available (missing for 5% of participants); otherwise, left ventricular hypertrophy was based on a qualitative assessment of mild, moderate, or severe hypertrophy, as described previously. 13 Baseline medication variables were ascertained using therapeutic classification codes recorded based on medications taken within 2 weeks of examination 1.
Statistical Analysis
We described examination 1 baseline characteristics of the study population by heart rate quintiles using frequencies with percentages for categorical variables and means with SDs or medians with interquartile ranges (IQRs) for continuous variables. Differences between groups were determined using χ 2 tests for categorical variables and Kruskal-Wallis tests for continuous variables.
We assessed outcomes of interest using heart rate as both a categorical variable and a continuous variable. As a categorical variable, the cumulative incidence of all-cause mortality (cohort A) and heart failure hospitalization (cohort B) were calculated by heart rate quintile using Kaplan-Meier estimates and tested for differences between the groups using log-rank tests. Unadjusted and adjusted associations between heart rate quintile and mortality and heart failure hospitalization outcomes were estimated using Cox proportional hazards regression models. As a continuous variable, we assessed the association of heart rate per 5-bpm increments with all-cause mortality and heart failure hospitalization. Covariates from the baseline examination used as adjustment variables in the models were derived from previous heart rate studies 1- . Data were censored for study participants at the time of participant loss to follow-up or the end of study event surveillance follow-up on December 31, 2011. For heart failure hospitalization, we also censored data for participants at the time of death. Data analysis was performed from July to October 2015. For all outcomes, we first tested for multicollinearity using the variance inflation factor of covariates and removed variables when this value exceeded 3. The linearity of continuous heart rate functional form was tested using Box-Tidwell 16 and supremum 17 tests and explored with polynomials and restricted cubic splines as indicated. Cox proportional hazards regression model estimates from the adjusted continuous heart rate models were used to calculate and plot adjust outcome rates by continuous heart rate with other covariates standardized to the mean. We performed an additional sensitivity analysis excluding participants with any ECG evidence of arrhythmia (including atrial fibrillation), prior myocardial infarction, or receiving nodal agents (ie, β-blocker, calcium channel blocker, and digoxin) or antiarrhythmic agents at examination 1. A modified Poisson model with an offset parameter was used to examine the development of elevated heart rate compared with stable or reduced heart rate in cohort C to adjust for the log of participant time between examinations 1 and 3 (range, 6-12 years). 18, 19 An increase in heart rate was defined as a greater than 5-bpm increase from baseline to ECG indicates electrocardiogram; HF, heart failure; HR, heart rate; and JHS, Jackson Heart Study.
follow-up, given the clinical relevance and preliminary examination of heart rate change distribution data. We used clinical judgment to select variables for the prediction model. As a sensitivity analysis, we changed the threshold to a greater than 10-bpm increase from baseline and repeated the analysis. Most variables had low missing rates. For those with less than 5% missing data, we imputed continuous variables to the overall median value, dichotomous variables to no value, and multichotomous variables to the most frequent categorical value. 20 For medication variables that were missing in 7% of participants, missing values were assigned to a separate category (coded as no, yes, or missing). A 2-tailed α = .05 level was used to establish statistical significance and report 95% CIs. Statistical analysis was performed with SAS, version 9.4 (SAS Institute Inc).
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Results Examination 1 was completed by 5304 participants. Figure 1 shows the derivation of the survival analysis cohort (cohort A) (n = 5261); the heart failure hospitalization analysis cohort (cohort B) (n = 5156), and the heart rate change analysis cohort (cohort C) (n = 3699). The overall median (25th-75th percentile) heart rate at baseline was 63 bpm (57-71 bpm). Participants in the highest heart rate quintile (73-118 bpm) included more women and had higher rates of heart failure, diabetes, hypertension, and chronic lung disease ( Table 1) . Participants in the highest quintile were also more likely to have higher body mass index, lower self-reported physical activity, and lower β-blocker use than other groups. For participants in cohort A, median (25th-75th percentile) follow-up was 8.9 years (8.1-9.7 years) and 510 participants (9.7%) died. Median follow-up for participants in cohort B was 7.0 years (7.0-7.0 years), and 329 individuals (6.4%) experienced hospitalization due to heart failure (eTable 1 in the Supplement). Median age was 55.7 (45.4-64.8) years. Table 2 reports the risks for death and heart failure hospitalization by heart rate quintile and per 5-bpm increase. Participants in the highest quintile had an increased mortality risk during the 8.9-year follow-up period before and after adjustment (eTable 1 in the Supplement and Figure 2) . After adjustment, every 5-bpm increase in heart rate was associated with a 14% increase in the hazard of mortality (Figure 2 ). Also after adjustment, elevated resting heart rate was associated with a 10% higher risk of heart failure hospitalization through 7 years of follow-up (eTable 1 in the Supplement and Figure 2) . BoxTidwell, supremum, and spline tests indicated linear functional form for continuous heart rate in both mortality and heart failure hospitalization models. Sensitivity analysis for participants without arrhythmias (including atrial fibrillation), prior myocardial infarction, as well as the use of nodal and antiarrhythmic agents at baseline revealed consistent findings for the association between heart rate and risk for all-cause mortality. Although the unadjusted results and the direction of the association persisted in the heart failure hospitalization sensitivity analysis, the analysis was underpowered (116 events) and the adjusted associations were not statistically significant (eTable 2 and eTable 3 in the Supplement).
Among the cohort of patients who completed examinations 1 and 3 (median [25th-75th percentile] time interval, 8 [7.4-8.4 years]), 974 individuals (26.3%) and 453 (12.2%) experienced heart rate increases of greater than 5 bpm and greater than 10 bpm, respectively (eFigure in the Supplement). Variables potentially affecting heart rate change were also assessed for this cohort. Diabetes, current smoking, and left bundle-branch block were associated with an increase in resting heart rate of 5 bpm after adjustment (Table 3) . β-Blocker therapy was not associated with a lower risk of elevated heart rate. In the sensitivity analysis (>10 bpm), adjusted risk ratios for diabetes and smoking were even higher, but there was no statistically significant association with left bundle-branch block (eTable 4 in the Supplement).
Discussion
We found a stepwise increase in the risk of all-cause mortality per quintile of baseline heart rate among Jackson Heart Study participants. Those with resting heart rates greater than 73 bpm had a more than 2-fold higher risk for mortality over 9 years, compared with participants in the lowest quintile, with higher cumulative incidence of death observed throughout the follow-up period. Elevated heart rate at baseline was also a risk factor for heart failure hospitalization when assessed as both a categorical variable and a continuous variable. Participants with diabetes and current smokers were at the highest risk for developing an elevated heart rate. Consideration of elevated heart rate as a therapeutic target has gained attention recently for patients with heart failure, 22 and our results have important implications for African American patients with heart failure. African American participants in the ARIC study 23 are more likely than white participants to develop heart failure (9.1 vs 6.0 per 1000 person-years among men; 8.1 vs 3.4 per 1000 person-years among women), and their disease is associated with worse morbidity and mortality, including 45% greater risk of death or functional decline. In addition, when adequately represented in corresponding trials, African American patients have responded differently to heart failure medications, including enalapril maleate, 24 hydralazine and isosorbide dinitrate combination, 25 and the β-blocker bucindolol. 26, 27 Our study expands on the current understanding of phenotypic similarities and differences among patients with heart failure. To our knowledge, this is the largest report identifying elevated resting heart rate as a risk factor for adverse outcomes among African American individuals. Our results extend the findings of previous studies 4,8,28-31 that consistently identified elevated resting heart rate as a risk factor for all-cause mortality and heart failure hospitalizations in predominantly white populations. Our findings also support those of the Multiethnic Study of Atherosclerosis (28% African American population), 32 which associated elevated resting heart rate with risk for incident heart failure. Our analysis of heart rate as a continuous variable revealed a linear association with mortality risk. In contrast, a threshold effect for increased risk for patients with a resting heart rate of higher than 70 to 75 bpm has been noted in previous studies 29-31 of the general population and for patients with heart failure. Cumulative incidence of mortality (A) and heart failure (HF) hospitalization (B) by quintile of baseline heart rate; and adjusted risk of mortality (C) and HF hospitalization (D) by continuous heart rate. Participants with higher resting heart rates were more likely to be women, to be physically inactive and obese, and to have diabetes and cardiovascular comorbid conditions. These participants were more likely to have heart failure and to receive heart failure therapies, including angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and diuretics, but less likely to receive β-blockers.
Several hypotheses have been proposed to explain the link between heart rate and survival. Development of myocardial energy depletion, ischemia, and calcium dysregulation is associated with tachycardia-mediated cardiomyopathy and may contribute to heart failure. 33 Underlying autonomic dysfunction and vagal or sympathetic tone imbalance marked by elevated heart rate may also negatively affect health. 4, 7, 34 Finally, although the prognostic value of heart rate in our cohort was statistically significant after adjustment for comorbid conditions, several conditions, including lung disease, renal disease, coronary artery disease, and heart failure, were associated with elevated resting heart rate. 35, 36 Change in heart rate between examinations 1 and 3 appeared to follow an approximately normal distribution with little change over time in our community-based cohort. We identified factors associated with elevated heart rate, which has been associated 16 with risk for all-cause mortality in a large heart failure cohort. Age at baseline was not associated with heart rate changes, perhaps because of follow-up duration. Participants with diabetes and current smokers were at high risk for an increase of greater than 5 bpm and greater than 10 bpm. Elevated heart rate in these populations may be a marker for associated coronary atherosclerotic changes or autonomic dysfunction for which they are at heightened risk. 5, 6 Elevated baseline heart rate was associated with a lower risk for developing a further increase in heart rate over time, which may be explained by regression to the mean and interim nonfatal events. The use of β-blockers at baseline and more daily physical activity had a nonsignificant association with elevated heart rate after adjustment.
Clinical Implications
African American patients presenting with higher resting heart rate are at increased risk for long-term adverse outcomes, including all-cause mortality and heart failure hospitalization. Increased heart rate is associated with smoking and diabetes, and further study is needed to understand factors contributing to its development.
Limitations
This was a retrospective analysis from an observational cohort study and the findings are therefore limited to associations. We adjusted for covariates in the analyses, but many covariates were obtained by self-report of participants. Also, although data were obtained using a well-validated digital ECG algorithm and with physician oversight to ensure accuracy, the resting heart rate values were derived from a single ECG at baseline. Our analysis therefore does not reflect day-to-day variations in heart rate or heart rate response to physical exertion, which may reveal additional insight into the association between heart rate and clinical outcomes. Although having the ECG assessed at 2 time points (examinations 1 and 3) is a study strength, ECG was not performed at examination 2 and therefore limited additional risk assessment for mortality and heart failure hospitalization. The analysis for heart failure hospitalization risk was limited by lack of data collection on heart failure events until 2005, potentially leading to an underestimated prognostic value of heart rate. The analysis of probability indicators of increased heart rate change was limited by 18% of participants who were alive but did not complete examination 3.
Conclusions
Elevated resting heart rate was associated with greater risk for mortality and heart failure hospitalization among African American participants in a large, community-based cohort. Participants with diabetes and smokers were most likely to develop elevated resting heart rate over time. These observations are similar to those seen in white populations, but further study is needed to assess the effect. 
